AbbVie posts strong Q3 results with $7.89B immunology sales, rising Elahere revenue, and Rinvoq Phase 3 success. Learn why ...

AbbVie raised its 2025 profit forecast on Friday, after strong sales of newer immunology drugs Skyrizi and Rinvoq helped ...

(Reuters) -AbbVie raised its 2025 profit forecast on Friday, after strong sales of newer immunology drugs Skyrizi and Rinvoq ...

AbbVie revealed it has raised its annual profit forecast for 2025 after sales of its newest immunology drugs Skyrizi and Rinvoq strengthened the company’s Q3 sales number, exceeding expectations set ...

AbbVie said on Friday the Trump administration was pushing for steeper cuts in this year's Medicare drug price negotiations, ...

The third quarter 2025 financial results and business update will be discussed during a conference call and webcast presentation today at 1:30 pm CET/8:30 am ET. A webcast of the live call and replay ...

Luc Teyton, professor in the Department of Immunology and Microbiology at Scripps Research, has received a five-year, $3.2 ...

AbbVie dipped early Friday, though the drug giant easily beat third-quarter forecasts on the back of its immunology meds.

Immunologists are begging people to exercise daily to support their immune system. It turns out that you can strengthen more ...

AbbVie raised its earnings guidance for 2025 and added to its quarterly dividend after another strong quarter of revenue ...

AbbVie Inc (ABBV) surpasses earnings expectations with robust growth in immunology and neuroscience, despite facing significant Humira sales decline.

Self-reported symptoms from eating gluten or wheat were reported by 10% of individuals without celiac disease or wheat ...